This page is the continuation of references in support of Section 8d Breast Cancer Treatment.
REFERENCES
Barrios, C., Forbes, J.F., Jonat, W., et al. (2012). The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol. 23(6), 1378-86. (Retrieved November 26th 2014): https://academic.oup.com/annonc/article/23/6/1378/170241
Baselga, J., Campone, M., Piccart, M., et al. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6), 520. (Retrieved November 26th 2014): https://www.nejm.org/doi/full/10.1056/NEJMoa1109653
Beresford, M., Tumur, I., Chakrabarti, J., et al. (2011). A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol (R Coll Radiol). 23(3), 209-15. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/books/NBK81846/
Blazeby, J.M,, Wilson, L., Metcalfe, C., Nicklin, J., English, R., Donovan, J.L (2006). Analysis of clinical decision-making in multi-disciplinary cancer teams. Ann Oncol 17: 457–460. (Retrieved November 26th 2014): https://academic.oup.com/annonc/article/17/3/457/146245
Brewster, A.M., Hortobagyi, G.N., Broglio, K.R., et al. (2008). Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16), 1179. (Retrieved November 26th 2014): https://academic.oup.com/jnci/article/100/16/1179/913378
Calman, K.C., Hine, J. (1995). A policy framework for commissioning cancer services. A report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, Department of Health: London 1995.
Cardoso, F., Bedard, P.L., Winer, E.P., et al. (2009). International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 101, 1174-1181. (Retrieved November 26th 2014): https://academic.oup.com/jnci/article/101/17/1174/906807
Carmichael, A.R., Anderson, E.D., Chetty, U., Dixon, J.M. (2003). Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol 29(1), 17. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pubmed?term=12559070
Carlson, R.W., Theriault, R., Schurman, C.M., et al. (2010). Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol. 28(25),3917. (Retrieved November 26th 2014): https://ascopubs.org/doi/full/10.1200/jco.2009.24.9565
Chia, S.K., Speers, C.H., D’yachkova, Y., et al. (2007). The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110(5), 973. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pubmed?term=17647245
Dent, R., Trudeau, M., Prtichard, K.I., et al. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13, 4429-4434. (Retrieved November 26th 2014): http://clincancerres.aacrjournals.org/content/13/15/4429.abstract?ijkey=ad41be49af6cf142381400d7987ff1782702889a&keytype2=tf_ipsecsha
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale, P., Taylor, C., Correa, C., et al. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935), 2127-35. (Retrieved November 26th 2014): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60488-8/fulltext
Farmer, H., McCabe, N., Lord, C.J. et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-21. (Retrieved November 26th 2014): https://www.nature.com/articles/nature03445
Feigelson, H.S., James, T.A., Single, R.M., et al. (2013). Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg. 216(5), 966. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678356/
Galimberti, V., Cole, B.F., Zurrida, S., et al. International Breast Cancer Study Group Trial 23-01 investigators. (2013). Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 14(4):297-305. (Retrieved November 26th 2014): https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70035-4/fulltext
Gilleard, O., Goodman, A., Cooper, M., Davies, M., Dunn, J. (2008). The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol 6, 61. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2459183/
Giordano, S.H., Buzdar, A.U., Smith, T.L., et al. (2004). Is breast cancer survival improving? Cancer 100(1), 44. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pubmed?term=14692023
Giuliano, A.E., Hunt, K.K., Ballman, K.V., et al. (2011). Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569. (Retrieved November 26th 2014): https://jamanetwork.com/journals/jama/fullarticle/645514
Goldhirsch, A., Gelber, R.D., Piccart-Gebhart, M.J., et al. Herceptin Adjuvant (HERA) Trial Study Team. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897):1021. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pubmed/23871490
Greenberg, P.A., Hortobagyi, G.N., Smith, T.L., et al. (1996). Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14(8), 2197. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pubmed?term=8708708
Hughes, L.L., Wang, M., Page, D.L., Gray, R., Solin, L.J., Davidson, N.E., Lowen, M.A., Ingle, J.N., Recht, A., Wood, W.C. (2009). Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27(32), 5319. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773217/
Keating, G.M. (2014). Bevacizumab: a review of its use in advanced cancer. Drugs. 74(16): 1891-925. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pubmed/25315029
Kesson, E.M., Allardice, G.M., George, W.D., Burns, H.J., Morrison, D.S. (2012). Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 344, e2718. (Retrieved November 26th 2014)
Lee, S.J., Schover, L.R., Partridge, A.H., et al. (2006). American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 24(18):2917. (Retrieved November 26th 2014): https://ascopubs.org/doi/full/10.1200/jco.2006.06.5888
Lynch, S.P., Lei, X., Chavez-MacGregor, M., et al. (2012). Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol. 23(12), 3063. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501230/
Mansel, R. E., Bogaerts, J., Rutgers, E. J. T. (2010). Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS Trial. Ann Surg Oncol. 17(7), 1854–1861. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889289/
Miller K,, Wang, M., Gralow, J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–2676. (Retrieved November 27th 2014): https://www.nejm.org/doi/full/10.1056/NEJMoa072113
Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., D’Amico, R. (2012). Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4, CD006243. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pubmed/22513938
National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. Retrieved November 6th 2014): http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
Newman, L.A. (2009). Epidemiology of locally advanced breast cancer. Semin Radiat Oncol. 19(4), 195. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pubmed/19732683
Nichol, A.M., Yerushalmi, R., Tyldesley, S., et al. (2011). A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes. J Clin Oncol. 29(36), 4763-8. (Retrieved November 26th 2014): https://www.nccn.org/professionals/physician_gls/default.aspx
Oppong, B.A., King, T.A. (2011). Recommendations for women with lobular carcinoma in situ (LCIS). Oncology 25(11), 1051-6. (Retrieved November 26th 2014): https://www.cancernetwork.com/oncology-journal/recommendations-women-lobular-carcinoma-situ-lcis
Peled, A.W., Irwin, C.S., Hwang, E.S., et al. (2014). Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol. 21(1), 37. (Retrieved November 26th 2014): https://link.springer.com/article/10.1245%2Fs10434-013-3230-0
Saini, K.S., Taylor, C., Ramirez, A-J., et al. (2011).Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Ann Oncol 23, 853–859. (Retrieved November 26th 2014): https://academic.oup.com/annonc/article/23/4/853/208665
Staley, H., McCallum, I., Bruce, J. (2012). Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 10, CD007847. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/23076938
UK Coordinating Committee on Cancer Research (UKCCCR). (2003). Ductal carcinoma in situ working party, radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: Randomised controlled trial. Lancet. 362:95–102. (Retrieved November 26th 2014): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)13859-7/fulltext
van de Water, W., Markopoulos, C., van de Velde, C.J., et al. (2012). Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA. 307(6), 590-7. . (Retrieved November 26th 2014): https://jamanetwork.com/journals/jama/fullarticle/1104959
